ResApp Health Limited (ASX:RAP) Managing Director and CEO Tony Keating provides an update on trial results, regulatory approval for the company's respiratory diagnosis and management smartphone app, and the market opportunity at FNN's Investor Event.
Key points: - Digital healthcare for respiratory disease
- Developing the world’s first respiratory disease diagnostic test
- Management tools for smartphones
- 700 million+ doctor visits annually for respiratory disease
- Preparing United States FDA, European CE and Australian TGA submissions
- Growing patent portfolio and data assets
For more, watch Managing Director and CEO Tony Keating present.
